Matches in Wikidata for { <http://www.wikidata.org/entity/Q89657483> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q89657483 description "2020 թվականի փետրվարի 11-ին հրատարակված գիտական հոդված" @default.
- Q89657483 description "article scientifique publié en 2020" @default.
- Q89657483 description "artículu científicu espublizáu en febreru de 2020" @default.
- Q89657483 description "scientific article published on 11 February 2020" @default.
- Q89657483 description "wetenschappelijk artikel" @default.
- Q89657483 description "наукова стаття, опублікована 11 лютого 2020" @default.
- Q89657483 name "Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany" @default.
- Q89657483 name "Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany" @default.
- Q89657483 type Item @default.
- Q89657483 label "Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany" @default.
- Q89657483 label "Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany" @default.
- Q89657483 prefLabel "Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany" @default.
- Q89657483 prefLabel "Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany" @default.
- Q89657483 P1433 Q89657483-A044CFC5-BE8D-49EB-8BAF-E0A3F4BC0124 @default.
- Q89657483 P1476 Q89657483-37DDE800-64D3-4ABE-A689-91875030F98A @default.
- Q89657483 P2093 Q89657483-0F48E306-F024-4B7E-94AC-9F47860C4C69 @default.
- Q89657483 P2093 Q89657483-6FDE923A-A854-489C-9B52-9E1F8C5A04A4 @default.
- Q89657483 P2093 Q89657483-B1368A08-4FD6-4A3B-9E35-F544EA37BDEB @default.
- Q89657483 P2093 Q89657483-CA8363C0-570D-4C0D-AC18-967646EB8FD1 @default.
- Q89657483 P304 Q89657483-5863E082-20AF-4F55-B643-9ECA0D376AA0 @default.
- Q89657483 P31 Q89657483-EF76B2C2-24F1-4274-9A95-FABBEE53D9C0 @default.
- Q89657483 P356 Q89657483-E3A85E4F-C5B1-4317-A621-112052869D39 @default.
- Q89657483 P577 Q89657483-AA0A1C35-299B-41DE-A0F1-17DEBFD6A831 @default.
- Q89657483 P698 Q89657483-822F634D-BF67-4EB7-A939-FAF78F762664 @default.
- Q89657483 P921 Q89657483-E15FC3A9-5732-43C6-988A-0DFCCA3F04F3 @default.
- Q89657483 P356 000506121 @default.
- Q89657483 P698 32045927 @default.
- Q89657483 P1433 Q15759019 @default.
- Q89657483 P1476 "Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany" @default.
- Q89657483 P2093 "Carsten Schmidt" @default.
- Q89657483 P2093 "Fiona Braegger" @default.
- Q89657483 P2093 "Karel Kostev" @default.
- Q89657483 P2093 "Ulf Helwig" @default.
- Q89657483 P304 "1-8" @default.
- Q89657483 P31 Q13442814 @default.
- Q89657483 P356 "10.1159/000506121" @default.
- Q89657483 P577 "2020-02-11T00:00:00Z" @default.
- Q89657483 P698 "32045927" @default.
- Q89657483 P921 Q917447 @default.